Critically ill COVID-19 patients and the role of Polymyxin B hemoperfusion
Over the last year, various works in literature have revealed the potential role of Polymyxin B Hemoperfusion in the management of non-responsive COVID-19 patients admitted to intensive care. We report here various case reports that have been presented as abstracts at international congresses and/or published in peer-reviewed journals on the use of Polymyxin B hemoperfusion in COVID-19 patients.
Highlights from Vicenza Course 2020
Interesting findings and new data on endotoxemia, endotoxic shock, implications in COVID-19 disease, role of Polymyxin B hemoperfusion and new approaches in septic AKI, were presented during the 38th International Vicenza Course on AKI and CRRT organized by Prof. Ronco which took place virtually from November 2-6 , 2020.
Septic AKI and role of the dialysis membrane
New perspectives in sepsis, particularly in septic AKI, and the role of the dialysis membrane were recently presented by Giuseppe Castellano at the national congress of SIN (Italian Society of Nephrology).
Exiting new results show the capability of a new PMMA membrane for continuous therapies of inhibiting complement system activation in LPS-induced AKI and lowering the transition from AKI to CKD damage, opening a new scenario in the management of septic AKI.
CKD, kidney transplantation and role of dialysis membrane
During the recent national congress of SIN (Italian Society of Nephrology) Prof. Grandaliano presented interesting concepts on the role of the dialysis membrane in CKD patients, in particular patients who are waitlisted for transplantation. In addition, promising results on the use of PMMA dialysis membrane in COVID-19 patients were presented.
